CIDP Treatment with Privigen – Phase IV

Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP

Protocol Description

The purpose of this study is to assess the effectiveness of a single dose of Privigen (IgPro10) for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in comparison to a multi-dose regimen. CIDP is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms caused by damage to the myelin protecting peripheral nerves throughout the body.

Study Level: Phase IV

Eligibility Criteria

Subject to certain inclusion and exclusion criteria, this study is enrolling participants ages 2 through 16 who have CIDP.
Boys and Girls: Ages 2 through 16

Requirements

Participants are randomly assigned to take either a single dose or multiple doses of Privigen.
Visits: 16 to 17
Duration: Up to 1 year

Status: Open to Enrollment

Source(s) of Support

CLS Behring

Primary Investigator

Maria L. Escolar, MD, MS

Contact Information

For more information about the study or enrollment, please contact:
Jodi Martin, Clinical Research Coordinator
412-692-6351